The physiology and emerging roles of antidiuretic hormone

International Journal of Clinical Practice

Volumn 56, Issue 10, 2002, Pages 777-782

  Singh Ranger, G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ADRENALIN; ATRIAL NATRIURETIC FACTOR; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HORMONE RECEPTOR; INSULIN; LIOTHYRONINE; NORADRENALIN; OPIATE; PEPTIDE HORMONE; STEROID; TERLIPRESSIN; VASOPRESSIN;

BLEEDING; CARDIOGENIC SHOCK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS VARICES; HEART ARREST; HEART ARRHYTHMIA; HEART HEMODYNAMICS; HEART INFARCTION; HEART SURGERY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; INTESTINE ISCHEMIA; ISCHEMIC HEART DISEASE; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; VASOPRESSIN RELEASE;

HEART ARREST; HEMORRHAGE; HEMOSTATICS; HUMANS; RENAL AGENTS; SHOCK; THORACIC SURGERY; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 0036962421     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Oliver H, Schafer E. On the physiological action of extracts of the pituitary body and certain other glandular organs. J Physiol (Lond) 1895; 18: 277-279.
2. Turner RA, Pierce JG, Du Vigneaud V. The purification and the amino acid content of vasopressin preparation. J Biol Chem 1951; 191: 21-28.
3. Sklar AH, Schrier RW. CNS mediators of vasopressin release. Physiol Rev 1983; 63: 1243-1280.
4. Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Inv 1974; 52: 2340-2352.
5. Schrier RW, Berl T, Anderson RJ. Osmotic and non-osmotic control of vasopressin release. Am J Physiol 1979; 236(4): F321-F332.
6. Bourque CW, Oliet SH, Richard D. Osmoreceptors, osmoreception, and osmoregulation. Front Neuroendocrinol 1994; 15: 231-274.
7. Bisset GW, Chowdrey HS. Control of release of vasopressin by neuroendocrine, reflexes. Q J Exp Physiol 1988; 73: 811-872.
8. Baraberis C, Moulliac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. J Endocrinol 1998; 156: 223-229.
9. Mouillac B, Chini B, Balestre MN et al. The binding site of neuropeptide vasopressin V1a receptor: evidence for a major localisation within transmembrane regions. J Biol Chem 1995; 270: 25771-25777.
10. Kurtzmann NA, Rogers PW, Boonjarern S. Effect of infusion of pharmacologic amounts of vasopressin on renal electrolyte excretion. Am J Physiol 1975; 228: 890.
11. Szczepanska-Sadowska E. Haemodynamic effects of a moderate increase of the plasma vasopressin level in conscious dogs. Pfliegers Arch 1973; 338: 313-322.
12. Laszlo FA, Laszlo F Jr, De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev 1991; 43: 73-108.
13. Liard JF, Deraiz O, Schelling P et al. Cardiac output distribution during vasopressin infusion or dehydration in conscious dogs. Am J Physiol 1982; 243: H663-H669.
14. Oyama H, Suzuki Y, Satoh S et al. Role of nitric oxide in the cerebral vasodilatory responses to vasopressin and oxytocin in dogs. J Cereb Blood Flow Metab 1993; 13: 285-290.
15. Vanhoutte PM, Katusic ZS, Shepherd JT. Vasopressin induces endothelium-dependent relaxations of cerebral and coronary, but not of systemic arteries. J Hypertens 1984; Suppl 12: S421-S422.
16. Lindner KH, Prengel AW, Pfenninger EG et al. Vasopressin improves vital organ blood flow during closed chest cardiopulmonary resuscitation in pigs. Circulation 1995; 91(1): 215-221.
17. Ericsson BF. Haemodynamic effects of vasopressin during haemorrhagic hypotension in the anaesthetised dog. Acta Chir Scand 1972; 138: 227-233.
18. Ericcson BF. Effect of vasopressin on the distribution of cardiac output and organ blood flow in the anaesthetised dog. Acta Chir Scand 1971; 137: 729-738.
19. Moreau R, Hadengue A, Soupison T et al. Abnormal pressor response to vasopressin in patients with cirrhosis: evidence for impaired buffering mechanisms. Hepatology 1990; 12(1): 7-12.
20. Tucci JR, Espiner EA, Jagger PI et al. Vasopressin in the evaluation of pituitary-adrenal function. Ann Intern Med 1968; 69: 191-202.
21. Aikawa T, Kashara T, Uchiyama M. Circadian variation of plasma arginine vasopressin concentration, or arginine vasopressin in enuresis. Scand J Urol Nephrol Suppl 1999; 202: 47-49.
22. Perras B, Pannenborg H, Marshall L et al. Beneficial treatment of age-related sleep disturbances with prolonged intranasal vasopressin. J Clin Psychopharmacol 1999; 19: 28-36.
23. Pittman QJ, Wlkinson MF. Central arginine vasopressin and endogenous antipyresis. Can J Physiol Pharmacol 1992; 70: 786-790.
24. Russ D, Walker BR. Role of nitric oxide in vasopressinergic pulmonary vasodilatation. Am J Physiol 1992; 262: H743-H747.
25. Jin HK, Chen YF, Yang RH et al. Vasopressin lowers pulmonary artery pressure in hypoxic rats by releasing atrial natriuretic peptide. Am J Med Sci 1989; 289: 227-236.
26. Walker BR, Haynes J Jr, Wang HL et al. Vasopressin-induced pulmonary vasodilatation in rats. Am J Physiol 1989; 257: H415-H422.
27. Eichenger MR, Walker BR. Enhanced pulmonary arterial dilatation to arginine vasopressin in chronically hypoxic rats. Am J Physiol 1994; 267: H2413-H2419.
28. Bichet DG, Razi M, Lonergan M et al. Haemodynamic and coagulation responses to 1-desamino[8.D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 1988; 318: 881-887.
29. Haslam RJ, Rosson GM. Aggregation of human blood platelets by vasopressin. Am J Physiol 1972; 223: 958-967.
30. Forrest P. Vasopressin and shock. Anaesth Intens Care 2001; 29: 463-472.
31. Singh-Ranger G. Vasopressin and shock. Anaesth Intens Care 2002; 30: 100.
32. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345(8): 588-595.
33. Wu W, Zbuzek V, Bellevue C. Vasopressin release during cardiac operation. J Thorac Cardiovasc Surg 1980; 79: 83-90.
34. Kuitanen A Hynynen M, Salmenpera M et al. Anaesthesia affects plasma concentrations of vasopressin, von Willebrand's factor, and coagulation factor VIII in cardiac surgical patients. Br J Anaesth 1993; 70: 173-180.
35. Levine FH, Philbin DM, Kono K et al. Plasma vasopressin levels and urinary sodium excretion during cardiopulmonary bypass with and without pulsatile flow. Ann Thorac Surg 1981; 32(1): 63-67.
36. Woods WGA, Forsling ML, Le Quesne LP. Plasma arginine vasopressin levels and arterial pressure during open heart surgery. Br J Surg 1989; 76: 29-32.
37. Forsling ML, Ingram DI, Stanier MW. Effects of various ambient temperatures and of heating and cooling the hypothalamus and cervical spinal cord on antidiuretic hormone secretion and urinary osmolality in pigs. J Physiol (Lond) 1976; 257: 673-686.
38. Argenziano M, Chen JM, Choudri AF et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998; 116(6): 973-980.
39. Morales DLS, Gregg D, Helman DN et al. Arginine vasopressin in the treatment of 50 patients with post cardiotomy vasodilatory shock. Ann Thorac Surg 2000; 69: 102-106.
40. Robinson RO, Pagliero KM. Polyuria after cardiac surgery. BMJ 1970; 3: 265-266.
41. Singh-Ranger G. Antidiuretic hormone replacement therapy to prevent or ameliorate vasodilatory shock. Med Hypoth 2002; 59(3): 337-340.
42. Argenziano M, Choudri AF, Oz MC et al. A prospective randomised trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96(9): 286-290.
43. Argenziano M, Chen JM, Cullinane S et al. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transpl 1999; 18: 814-817.
44. Rosenzweig EB, Starc TJ, Chen JM et al. Intravenous arginine vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 1999; 100(suppl II): 182-186.
45. Cowley AW Jr, Monos E, Guyton AC. Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res 1974; 34: 505-514.
46. Garrard CS, Kontoyannis DA, Piepoli M. Spectral analysis of heart rate variability in the sepsis syndrome. Clin Auton Res 1993; 3: 5-13.
47. Landry DW, Oliver JA. The ATP sensitive potassium channel mediates hypotension in endotoxaemia and hypoxic lactic acidosis in the dog. J Clin Invest 1992; 89: 2071-2074.
48. Malay MB, Ashton RC Jr, Landry DW et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999; 47: 699-703.
49. Tetsuka T, Nakaya Y, Inoue I. Arginine vasopressin inhibits interleukin-1 beta stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cells. J Hypertens 1997; 15: 627-632.
50. Landry DW, Levin HR, Gallant EM et al. Vasopressin deficiency contributes to the vasodilatation of septic shock. Circulation 1997; 95(5): 1122-1125.
51. Brackett DJ, Schaefer CF, Tompkins P et al. Evaluation of cardiac output, total peripheral resistance, and plasma concentrations of vasopressin in the conscious unrestrained rat during endotoxaemia. Circ Shock 1985; 17: 273-284.
52. Wilson MF, Brackett DJ, Hinshaw LB et al. Vasopressin release during sepsis and septic shock in baboons and dogs. Surg Gynec Obstet 1981; 153: 869-872.
53. Lindner K, Prengel P, Pfenninger E et al. Vasopressin improves vital organ blood flow during closed-chest cardiopulmonary resuscitation in pigs. Circulation 1995; 91: 215-221.
54. Wenzel V, Lindner K, Prengel A et al. Vasopressin improves vital organ blood flow after prolonged cardiac arrest with post-countershock pulseless electrical activity in pigs. Crit Care Med 1999; 27: 486-492.
55. Lindner KH, Dirks B, Strohmenger HU et al. Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997; 349: 535-537.
56. Stiell IG, Hebert PC, Wells GA et al. Vasopressin versus epinephrine for in-hospital cardiac arrest: a randomised controlled trial. Lancet 2001; 358: 105-109.
57. ECC Guidelines. Advanced cardiovascular life support: introduction to ACLS 2000. Overview of recommended changes to the ACLS from the guidelines 2000 conference. Circulation 2000; 102: I-129-I-135.
58. Wenzel V, Ewy G, Lindner K. Vasopressin and endothelin release during cardiopulmonary resuscitation. Crit Care Med 2000; 28: N233-N235.
59. Morales MD, Madigan J, Cullinane S et al. Reversal by vasopressin of intractable hypotension in the late phase of haemorrhagic shock. Circulation 1999; 100: 226-229.
60. Voelckel W, Lurie K, Lindner K et al. Vasopressin improves survival after cardiac arrest in hypovolemic shock. Anesth Analg 2000; 91: 627-634.
61. Novitsky D, Wicomb WN, Cooper DKC et al. Electrocardiographic, haemodynamic and endocrine changes occurring during experimental brain death in the Chacma baboon. Heart Transpl 1984; 4: 63-69.
62. Wheeldon DR, Potter CDO, Jonas M et al. Using 'unsuitable' hearts for transplantation. Eur J Cardiothorac Surg 1994; 8: 7-10.
63. Yoshioka T, Sugimoto H, Uenishi M et al. Prolonged haemodynamic maintenance by the combined administration of vasopressin and epinephrine in brain death: a clinical study. Neurosurgery 1986; 18: 565-567.
64. Wheeldon DR, Potter CDO, Oduru A et al. Transforming the 'unacceptable' donor: outcomes from the adoption of a standardised donor management technique. J Heart Lung Transpl 1995; 14: 734-742.
65. Kehne JH, Hughes FA, Gompertz ML. The use of surgical pitruitin in the control of oesophageal varix bleeding. Surgery 1956; 39: 917-925.
66. Ready JB, Robertson Ad, Rector WG. Effects of vasopressin on portal pressure during haemorrhage from oesophageal varices. Gastroenterology 1991; 100: 1411-1416.
67. Ioannou G, Doust J, Rockey DC. Terlipressin for acute oesophageal variceal haemorrhage (Cochrane Review). Cochrane Library 2002, Issue 2.
68. Full prescribing information for pitressin. In: American Hospital Formulary Service (AHFS) Drug Information online. http://www.ashp.org/ahfs
69. Hypothalamic and pituitary hormones. In: Reynolds J, Ed. Martindale: the extra pharmacopoeia, 29th edn. London: Pharmaceutical Press 1989; 1138.